A phase 2 trial of the novel antibiotic ridinilazole in adults with Clostridium difficile infections showed that it performed better than vancomycin, one of three drugs used to routinely treat infections, and was well tolerated, with a similar adverse event profile.
Within 2 months of admission, 29% of C diff patients died, compared with 14% of the control group.
A 16-study meta-analysis finds about a 50% higher risk tied to anti-reflux drugs.
More details emerged today on President Donald Trump's proposed budget, including plans to drastically cut research grant funding to the National Institutes of Health (NIH) in the current fiscal year, which ends in October.
In a study that expands on an earlier analysis, screening of blood donations in Puerto Rico last spring and summer found a 13% incidence of Zika virus, according to a study yesterday in Emerging Infectious Diseases.
Appropriate use of the "watchful waiting" strategy for management of acute otitis media (AOM) in children could reduce healthcare costs and improve health outcomes, according to a new study in Pediatrics.
Israel and four European countries reported more highly pathogenic H5N8 outbreaks, according to the latest updates from the World Organization for Animal Health (OIE). Israel reported six new outbreaks in the central part of the country, with start dates ranging from Jan 23 to Feb 12, five of them at farms (turkeys, ducks, and laying hens) and one involving three barn owls found dead at a nature park.
The drug may cut all-cause mortality in patients with severe C difficile infection.
More than 90% of Veterans Health Administration (VHA) hospitals have developed written antimicrobial stewardship policies, and the agency's Antimicrobial Stewardship Initiative has cut antibiotic use 12% overall so far, VHA officials noted yesterday in an analysis in Infection Control and Hospital Epidemiology.
Two phase 3 trials showed that a human mononoclonal antibody cut recurrence about 40%.
